TECHNOLOGY

Medicinal Nanoengineering™ Platform

BIND Biosciences is developing targeted therapeutics that deliver high drug concentrations to target cells and tissues with precisely controlled pharmacokinetic and pharmacodynamic properties resulting in increased efficacy and reduced toxicity.  Our Medicinal Nanoengineering platform allows us to develop drugs predictably, cost effectively and rapidly.  Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications or life cycle extension for mid- and late-stage products.

BIND Medicinal Nanoengineering™ platform allows it to (i) precisely engineer libraries of drug encapsulated targeted nanoparticles that differ systematically in their biophysicochemical properties; (ii) screen for targeted nanoparticles with optimal drug PK; biodistribution; cell- or tissue-specific targeting; and drug exposure kinetics; and (iii) manufacture candidate drug encapsulated targeted nanoparticles using scalable unit operations. BIND’s targeted nanoparticles concentrate drugs at the site of disease while minimizing systemic exposure, thereby increasing efficacy and reducing side effects. Our initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics.  Significant and varied barriers to entry result in lengthened market exclusivity of nanoengineered products. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.

The fluorescence microscope image below reveals cytosolic accumulation through receptor mediated endocytosis of targeted nanoparticles specifically targeted to a cell-surface antigen:

Targeted Nanoparticle Platform

BIND’s targeted nanoparticles consist of the following components that facilitate optimization and control: 
 

Targeting ligand provides recognition, enabling targeted nanoparticles to identify and bind to their intended target site. They are designed to recognize specific proteins or receptors that are found on the surface of cells involved in disease or the surrounding extracellular matrix.

Surface functionalization shields targeted nanoparticles from immune surveillance, while providing attachment for the targeting ligand through proprietary linkage strategies. We have developed proprietary methods for precisely controlling the surface characteristics necessary to ensure the drug is delivered efficiently and consistently.

Polymer matrix encapsulates payload molecules in a matrix of clinically validated biodegradable and biocompatible polymers that can be designed to provide the desired drug release profile.

Therapeutic payloads can be incorporated into our targeted nanoparticles, including small molecules, peptides, proteins and nucleic acids, such as siRNA.

Intellectual property 

BIND's intellectual property portfolio consists of a broad patent estate of over 50 patent families issued and pending patent applications covering long-circulating nanoparticles, targeted nanoparticles, controlled release polymer systems and nanoparticle synthesis. Key foundational intellectual property has been licensed on an exclusive and worldwide basis from MIT and Brigham and Women’s Hospital – Harvard Medical School.